SCHEMBL1199784

SCHEMBL1199784

CCC1OC1(C)C(=O)OC

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175636 0.82 ALDH1A1 (0.36)
SCHEMBL14967021 0.81 EPHX1 (0.33)
SCHEMBL14968046 0.79 HCRTR2 (0.32)
SCHEMBL14968347 0.79 TSHR (0.32)
SCHEMBL14967927 0.78 EPHX1 (0.41)
SCHEMBL14967611 0.78 EPHX1 (0.38)
SCHEMBL14968298 0.77 EPHX1 (0.44)
SCHEMBL14967674 0.76 ALDH1A1 (0.42)
SCHEMBL14967647 0.73
SCHEMBL9692331 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301397-B2 Method for producing polydienes and polydiene copolymers with reduced cold flow BRIDGESTONE CORPORATION (JP) 2019-05-28 US disclosed
US-20160340447-A1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW BRIDGESTONE CORPORATION (JP) 2016-11-24 US disclosed
US-9458270-B2 Method for producing polydienes and polydiene copolymers with reduced cold flow BRIDGESTONE CORPORATION (JP) 2016-10-04 US disclosed
EP-2780177-B1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW BRIDGESTONE CORP (JP) 2016-03-23 EP disclosed
US-20140296445-A1 Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow BRIDGESTONE CORPORATION (JP) 2014-10-02 US disclosed
EP-2780177-A1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW Bridgestone Corporation (JP) 2014-09-24 EP disclosed
US-8609873-B2 Process for making and using HOF.RCN THE SECRETARY OF STATE FOR DEFENSE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 2013-12-17 US disclosed
US-8609873-B2 Process for making and using HOF.RCN THE SECRETARY OF STATE FOR DEFENSE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 2013-12-17 US disclosed
US-8609873-B2 Process for making and using HOF.RCN THE SECRETARY OF STATE FOR DEFENSE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 2013-12-17 US disclosed
WO-2013075074-A1 METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW BRIDGESTONE CORPORATION (JP) 2013-05-23 WO disclosed
US-20110040092-A1 PROCESS FOR MAKING AND USING HOF.RCN THE SECRETARY OF STATE FOR DEFENSE (GB) 2011-02-17 US disclosed
US-20110040092-A1 PROCESS FOR MAKING AND USING HOF.RCN THE SECRETARY OF STATE FOR DEFENSE (GB) 2011-02-17 US disclosed
US-20110040092-A1 PROCESS FOR MAKING AND USING HOF.RCN THE SECRETARY OF STATE FOR DEFENSE (GB) 2011-02-17 US disclosed
EP-2188046-A2 A PROCESS FOR MAKING AND USING HYPOFLUOROUS ACID (HOF)/NITRILE (RCN) COMPLEXES . The Secretary of State For Defence (GB) 2010-05-26 EP disclosed
WO-2009030928-A2 A PROCESS FOR MAKING AND USING HOF.RCN THE SECRETARY OF STATE FOR DEFENCE (GB) 2009-03-12 WO disclosed
EP-0153692-B1 METHOD FOR ISOMERIZATION A GLYCIDATE DERIVATIVE SAGAMI CHEMICAL RESEARCH CENTER (JP) 1992-07-29 EP disclosed
US-4621150-A METAL PERHALATE OR SULFONATE OR COMPLEX; GLYCIDATE, 2-HYDROXY-3-BUTENOATE, EPOXIDE SAGAMI CHEMICAL RESEARCH CENTER (JP) 1986-11-04 US disclosed
EP-0153692-A2 Method for isomerization a glycidate derivative SAGAMI CHEMICAL RESEARCH CENTER (JP) 1985-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110040092-A1 PROCESS FOR MAKING AND USING HOF.RCN HMOX2, FSCN1, POLN IDO1 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.